In addition, β-adrenergic receptor blockers and angiotensin-converting enzyme (ACE) inhibitors, HF therapeutic agents that provide morbidity and mortality benefits, reverse ventricular dilation and systolic dysfunction, further supporting the importance of clinical cardiac remodeling as HF therapeutic targets [4,5]. The gene discussed is ACE; the disease is hydrops fetalis.